Price Chart

DATE TIME TYPE PERIOD REPORTED
EPS
ESTIMATED
EPS
SURPRISE
07/29/2022* -- Results Q2 2022 -- -0.15 --
07/29/2022* 08:00 EST Earnings Call Q2 2022 -- -- --
04/28/2022 -- Results Q1 2022 -0.04 -0.19 79.11%
04/28/2022 08:00 EST Earnings Call Q1 2022 -- -- --
02/24/2022 -- Results Q4 2021 -0.25 -0.10 -144.5%
02/24/2022 08:00 EST Earnings Call Q4 2021 -- -- --
10/28/2021 -- Results Q3 2021 -0.13 -0.06 -106.6%
10/28/2021 08:00 EST Earnings Call Q3 2021 -- -- --
*Estimated Date/Time

Earnings

Next Report Date 07/29/2022 (est.)
EPS Estimate Upgrade
Last Actual EPS Upgrade

Loading chart...
Last Report Date 04/28/2022
Beat/Miss Upgrade
Return Since -3.21%
Last FQE 03/31/2022
Next FQE 06/30/2022

Profile

Edit
NovoCure Ltd serves in the healthcare sector of the United States. Its business involves commercial-stage oncology operations involving therapies to cure critical tumors. Its pipeline consists of Ovarian Cancer, Pancreatic Cancer, Non-Small Cell Lung Cancer, and Brain Metastasis. NovoCure derives its major revenues in the United States.
URL https://www.novocure.com
Investor Relations URL https://www.novocure.com/investor-relations/
HQ State/Province N/A
Sector Healthcare
Industry Medical Instruments & Supplies
Equity Style Mid Cap/Growth
Next Earnings Release Jul. 29, 2022 (est.)
Last Earnings Release Apr. 28, 2022
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Dividends

Dividend Per Share (TTM) --
2017
2018
2019
2020
2021
No data available
 
6.00%
4.00%
2.00%
 
Yield to Market 0.00
Yield to Sector 0.00
Yield to Industry 0.00
Last Dividend Amt. --
Dividend Frequency --
Last Ex-Dividend Date --
Yield (TTM) 0.00%
Forward Yield --
Payout Ratio 0.00%
Cash Payout Ratio 0.00%
Consistent Payer (5Y) No
Consistent Growth (5Y) No

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Total Returns Comparison

Edit comparables

Annual Total Returns Versus Peers

Edit comparables
Loading chart...
Name
2015
2016
2017
2018
2019
2020
2021
YTD
--
-64.89%
157.3%
65.74%
151.7%
105.3%
-56.61%
-0.51%
1.38%
11.96%
21.83%
-4.38%
31.49%
18.40%
28.71%
-17.67%
-17.91%
-0.34%
83.12%
14.96%
115.8%
49.32%
4.08%
-25.31%
5.92%
-41.45%
103.4%
10.58%
32.13%
7.94%
-7.08%
17.76%
41.48%
-84.98%
-1.59%
48.39%
-89.18%
2.70K%
28.30%
-62.66%
32.33%
-32.38%
2.42%
-0.65%
0.53%
28.66%
30.72%
4.69%
As of May 20, 2022.

Profile

Edit
NovoCure Ltd serves in the healthcare sector of the United States. Its business involves commercial-stage oncology operations involving therapies to cure critical tumors. Its pipeline consists of Ovarian Cancer, Pancreatic Cancer, Non-Small Cell Lung Cancer, and Brain Metastasis. NovoCure derives its major revenues in the United States.
URL https://www.novocure.com
Investor Relations URL https://www.novocure.com/investor-relations/
HQ State/Province N/A
Sector Healthcare
Industry Medical Instruments & Supplies
Equity Style Mid Cap/Growth
Next Earnings Release Jul. 29, 2022 (est.)
Last Earnings Release Apr. 28, 2022
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Top Fund Holders

Symbol Dollars Invested % Weight
ITEQ 4.494M USD 3.82%
DYN1583 14.32M USD 2.69%
TFCGX 1.249M USD 2.68%
DSGFX 5.185M USD 2.42%
ISRA 1.379M USD 2.08%
HTEC 2.146M USD 1.82%
XHE 7.160M USD 1.77%
BTEC 913954.0 USD 1.70%
BGGKX 1.008M USD 1.58%
F00001682N 1.665M USD 1.56%
IHI 43.19M USD 0.62%
CSPFX 300.05M USD 0.42%

Top Portfolio Holders

0 of 0

Other Resources

Whale Wisdom 13F Filings
Seeking Alpha Call Transcripts
Morningstar Insider Trading
Nasdaq Institutional Ownership
Nasdaq Option Chain
SEC SEC Filings
Twitter NVCR Tweets